Results 141 to 150 of about 4,356 (162)

Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF

JACC: Heart Failure
Chronic kidney disease (CKD) is defined by the KDIGO (Kidney Disease: Improving Global Outcomes) guideline as abnormal kidney structure or function, present for >3 months, with implications for health. KDIGO-defined CKD is associated with poor outcomes in patients with heart failure (HF).
Samir Patel, Venkatesh K. Raman, Charles Faselis, Gregg C. Fonarow, Phillip H. Lam, Amiya A. Ahmed, Paul A. Heidenreich, Stefan D. Anker, Prakash Deedwania, Charity J. Morgan, Sijian Zhang, Hans Moore, Janani Rangaswami, George Bakris, Javed Butler, Helen M. Sheriff, Richard M. Allman, Qing Zeng-Treitler, Wen-Chih Wu, Ali Ahmed   +19 more
openaire   +3 more sources

I fenotipi dello scompenso cardiaco: HFrEF, HFmrEF, HfpEF. Diagnosi, prognosi e terapie differenziali

Cardiologia Ambulatoriale, 2023
La classificazione dello scompenso cardiaco (SC) secondo i livelli di frazione di eiezione (FE) non è sufficiente per un corretto inquadramento clinico e per le scelte terapeutiche. Nonostante questo, la suddivisione nelle diverse fasce di FE (FE ridotta, moderatamente ridotta, preservata – HFrEF, HFmrEF, HfpEF) è utile per un iniziale inquadramento ...
openaire   +1 more source

Dapagliflozin improves outcomes in HFmrEF and HFpEF

Nature Reviews Cardiology, 2022
openaire   +2 more sources

Dapagliflozin DELIVERs for HFmrEF/HFpEF

Medicom Conference Report ESC 2022, 2022
openaire   +1 more source

[Heart failure with reduced left ventricular ejection fraction (HFrEF, HFmrEF)].

Therapeutische Umschau. Revue therapeutique
Heart failure is the final stage of most heart diseases and, with over 64 million people affected worldwide, is considered a global pandemic. The prevalence is expected to continue to rise. The prevention and treatment of cardiovascular diseases and the early detection of patients suffering from heart failure are essential.
Thomas, Seiler, Matthias, Paul
openaire   +1 more source

Dapagliflozin wirkt bei HFpEF und HFmrEF Glykämie-unabhängig

Diabetologie und Stoffwechsel, 2023
openaire   +1 more source

Who wants the middle seat?: HFmrEF in a world dominated by HFpEF and HFrEF

Journal of Cardiac Failure, 2023
Peter M, Eckman, Ruben, Crespo
openaire   +2 more sources

CLINICAL PREDICTORS OF ONE-YEAR TRAJECTORY OF EJECTION FRACTION IN PATIENTSWITH HFMREF

Journal of the American College of Cardiology, 2023
Apoorva Gangavelli, Zihao Liu, Jeffrey Wang, Alexis K. Okoh, Rebecca S. Steinberg, Krishan Patel, Alanna A. Morris   +6 more
openaire   +1 more source

How to Measure DELIVERed Benefits of Dapagliflozin in the Management of HFmrEF/HFpEF?

JACC: Heart Failure, 2023
Atsushi Tanaka, Kosuke Sawami, Koichi Node   +2 more
openaire   +2 more sources

HFpEF and HFmrEF: Different Sides of the Same Coin?

2022
openaire   +1 more source